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ABSTRACT  
The development of photoactivatable metal complexes with potential anticancer properties is a 
topical area of current investigation. Photoactivated chemotherapy (PACT) using coordination 
compounds is typically based on photochemical processes occurring at the metal center. In the 
present study, an innovative approach is applied that takes advantage of the remarkable 
photochemical properties of diarylethenes. Following a proof-of-concept study with two 
complexes, namely C1 and C2,1 a series of additional platinum(II) complexes from 
dithienylcyclopentene-based ligands have been designed and prepared. Like C1 and C2, these new 
coordination compounds exhibit two thermally stable, interconvertible photoisomers that display 
distinct properties. The photochemical behavior of ligands L3─L7 has been analyzed by 1H NMR 
and UV-vis spectroscopy. Subsequently, the corresponding platinum(II) complexes C3─C7 have 
been synthesized and fully characterized, including by X-ray diffraction for some of them. Next, 
the interaction of each photoisomer (i.e., containing the open or closed ligand) of the metal 
complexes with DNA has been examined thoroughly using various techniques, revealing their 
distinct DNA-binding modes and affinities, as observed for the earlier compounds C1 and C2. The 
antiproliferative activity of the two forms of the complexes has then been assessed with five cancer 
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cell lines and compared with that of C1 and C2, which supported the use of such diarylethene-
based systems for the generation of a new class of potential photochemotherapeutic metallodrugs. 
 
INTRODUCTION 
 
An elegant drug-design approach aimed at enhancing tumor selectivity while reducing systemic 
toxicity is the use of light activation.2 Recent advances in laser and fiber-optic technologies have 
driven the development of various medical applications based on light,3 including the design of 
metal-containing prodrugs that can be activated through irradiation.2, 4 Photoactivated 
chemotherapy (PACT) is a prominent field of investigation, which provides both temporal and 
spatial control over drug activity, and offers tremendous potential for the treatment of different 
types of cancer.5 
 Photoactivatable prodrugs based on coordination compounds typically involve activation 
at the metal center, with concomitant generation of pharmacologically active species.6 Metal-
mediated PACT can be achieved via distinct mechanisms of action, namely photodissociation7 and 
photosensitisation,8 which are often associated to the redox properties of the metal center,2 and 
photothermal reaction.9 A number of research groups worldwide are developing elegant systems 
that are photoactivatable through the action of light on the metal.10-17 
 The activation of a metallodrug through the photomodification of a coordinated ligand has 
not been investigated extensively. Different types of organic molecular photoswitches may be used 
for this purpose, like azobenzenes, spiropyrans or diarylethenes.18 Azobenzenes and spiropyrans 
are thermally unstable and gradually revert back to their initial state in the absence of light.19 In 
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contrast, diarylethenes are more suitable for such biological application as they exhibit negligible 
thermal relaxation; as a matter of fact, these unique properties have converted them as one of the 
most interesting classes of photoresponsive molecular devices, as reflected by their numerous 
applications.20 
In the present study, the potential use of diarylethene moieties to generate potential light-
activatable metallodrugs has been investigated further.1 Indeed, it has recently been shown that the 
two thermally stable states of two molecular switches (complexes C1 and C2 in Figure 1) exhibit 
distinct biological activities, one of the two photoisomers being cytotoxic whereas the other one 
not.1 Hence, based on these results, a series of new simple diarylethene-based ligands were 
designed and prepared, and the corresponding platinum(II) complexes were synthesized. 
Subsequently, the DNA-interacting properties of their open and closed forms were examined using 
various techniques, and their cytotoxic behavior against various cancer cell lines was then 
evaluated and compared with those of C1 and C2. Promising results were achieved, further 
indicating that this innovative mechanism of photochemical control may be applied to produce a 
new class of photoactivatable metallodrugs. It can indeed be stressed that the photoactivation of 
the cytotoxic properties of the platinum(II) compounds reported herein is based on the 
photomodification of the coordinated ligand, and not on the metal center (as commonly described 
in the literature). 
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Figure 1. A) Reversible photocyclization of dithienylcyclopentenes (R = H) and 
dithienylperfluorocyclopentenes (R = F); B) Schematic representation of the platinum(II) 
complexes C1-C7, obtained with seven different Dithienylcyclopentene-based ligands. 
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EXPERIMENTAL DETAILS 
 
Materials and methods. All reagents and HPLC-grade solvents for the synthesis of the 
ligands and complexes were purchased from commercial sources and used as received. Ethidium 
bromide, sodium cacodylate, TAE (Tris Acetate-EDTA) and calf thymus DNA (ct-DNA) were 
purchased from Sigma-Aldrich. Plasmid pBR322 DNA was purchased from Roche. All reagents 
used for the in vitro DNA-interaction studies were obtained from Sigma-Aldrich and Invitrogen. 
Anhydrous solvents were distilled under an inert atmosphere using a PureSolv™ solvent 
purification system from Innovative Technologies. 
When required, the reactions were performed under an atmosphere of dinitrogen using 
standard procedures. Column chromatography purifications were carried out in air, using ultrapure 
silica gel (60-200 μm, 60 Å) from Acros Organics, and monitored by analytical thin-layer 
chromatography (TLC) using pre-coated aluminum plates. 
Nuclear magnetic resonance (NMR) spectra were recorded at 298 K on a Varian Mercury 400 
MHz spectrometer. Chemical shifts (δ) are reported in ppm and coupling constants (J) are given 
in Hz. Proton chemical shifts are referenced to the corresponding non-deuterated solvent peak 
(CHCl3: 7.26 ppm; DMSO: 2.50 ppm); fluorine chemical shifts are referenced to trifluoroacetic 
acid (─76.55 ppm). Signal multiplicities are defined as s (singlet), d (doublet), t (triplet), q 
(quartet), quint (quintet), br (broad signal) and m (multiplet). 
ESI mass spectrometry was carried out using a LC/MSD-TOF spectrometer from Agilent 
Technologies equipped with an electrospray ionization (ESI) source, at the Centres Cientifics i 
Tecnologics de la Universitat de Barcelona. Samples were eluted with a H2O/CH3CN 1:1 mixture 
and measured in the positive mode. C, H, N and S elemental analyses were performed at the 
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Centres Cientifics i Tecnologics de la Universitat de Barcelona, using a Thermo EA 1108 CHNS/O 
analyzer from Carlo Erba Instruments. 
Spectroscopic measurements in buffered aqueous media were performed in cacodylate buffer 
solution (1 mM sodium cacodylate, 20 mM NaCl, pH = 7.2), which was prepared with ultrapure 
water and whose pH was adjusted with HClaq. The UV and visible irradiation of the samples was 
carried out with a MAX-303 light source from Asahi Spectra, using appropriate bandpass filters. 
The UV-Vis absorption spectra were recorded on a Varian Cary 100 Bio spectrophotometer. 
Fluorescence and circular dichroism spectra were collected in 1 cm-pathlength quartz cuvettes, 
using cacodylate buffered solutions. 
The stock solutions for the DNA-interaction studies were prepared as follows: the commercial 
plasmid pBR322 stock solution (250 μg mL─1, ca. 385 μMbp) was used as received. A 150 μM 
stock solution of ct-DNA was prepared by dissolving the highly-polymerized sodium salt of the 
biomolecule in cacodylate buffer, and the exact concentration was determined by absorbance at 
260 nm (εbp = 13200 M─1 cm─1). 5 mM stock solutions of the studied complexes were freshly 
prepared in DMSO before each experiment, and further diluted in DMSO/buffer mixtures as 
required. Stock solutions of closed complexes were obtained by irradiation of the corresponding 
solutions of the open complexes, at λ < 365 nm, until reaching the photostationary state (PSS). 
 
Synthesis 
1,5-Bis(5-chloro-2-methyl-3-thienyl)pentane-1,5-dione (1).21 Aluminum(III) trichloride (29.0 
g, 217 mmol) was slowly added to a mixture of 2-chloro-5-methylthiophene (25.0 g, 189 mmol) 
and glutaryl dichloride (12.0 mL, 94 mmol) dissolved in 200 mL of ice-cold nitromethane. After 
the addition of AlCl3, the resulting dark red solution was stirred for 3 h at room temperature and 
150 mL of ice-cold water were subsequently added in small portions. The reaction mixture was 
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then placed in an ice bath and vigorously stirred for 1 h, until an abundant precipitate formed. This 
precipitate was then poured over a glass filter, washed with cold n-pentane and finally dried under 
reduced pressure to yield the crude final product 1 as a pale brown solid (27.6 g, 81%). 
1H NMR (400 MHz, CDCl3): δ = 2.06 (m, 2H, J = 6.8 Hz, CH2), 2.66 (s, 6H, Me), 2.86 (t, 4H, 
J = 6.8 Hz, COCH2), 7.18 (s, 2H, thiophene). MS (ESI): m/z = 361 [M]+ (expected: 360.98). 
Elemental analyses calculated for C15H14Cl2O2S2 (%): C 49.86, H 3.91, S 17.75; found: C 50.19, 
H 3.94, S 16.56. 
1,2-Bis(5-chloro-2-methyl-3-thienyl)cyclopentene (2). Titanium(IV) tetrachloride (4.4 mL, 40 
mmol) was carefully added under a nitrogen atmosphere using a syringe to an ice-cooled 
suspension of zinc dust (5.2 g, 80 mmol) in 150 mL of anhydrous THF. The resulting grey-blue 
reaction mixture was slowly heated to 50 °C and stirred for 2 h, after which pyridine (3.2 mL, 40 
mmol) was added dropwise, producing a brown solution. After 10 min, 1 (7.2 g, 20 mmol) was 
added and the resulting mixture was stirred in the dark overnight. Next, the solution was cooled in 
an ice bath and quenched with a 20% aqueous K2CO3 solution (25 mL), yielding an abundant black 
precipitate. After vigorous stirring of the precipitate with diethyl ether (40 mL), the remaining 
solid was isolated by filtration over a glass filter and washed with additional diethyl ether (2 × 25 
mL). The combined organic phase was placed in an ice bath for 30 min and filtered again to 
eliminate the resulting undesired white precipitate. The solution was washed with acidified water 
(2 × 20 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give an orange 
oil. This oil was purified by column chromatography on silica gel with cyclohexane as the eluent, 
yielding an oil that slowly solidified to colorless product 2 (4.75 g, 72%). 
1H NMR (400 MHz, CDCl3): δ = 1.88 (s, 6H, Me), 2.02 (m, 2H, J = 7.6 Hz, cyclopentene), 2.71 
(t, 4H, J = 7.6 Hz, cyclopentene), 6.57 (s, 2H, thiophene). MS (ESI): m/z = 329 [M]+ (expected: 
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328.99). Elemental Analyses calculated for C15H14Cl2S2 (%): C 54.71, H 4.29, S 19.47; found: C 
54.89, H 4.37, S 18.78. 
4-Bromo-5-methylthiophene-2-boronic acid (3). n-Buthyllithium (10 mL of a 1.6 M solution 
in hexane, 16.0 mmol) was added dropwise to a solution of 3,5-dibromo-2-methylthiophene (2.0 
mL, 15.6 mmol) in anhydrous diethyl ether (25 mL) at ─78 °C, under a dinitrogen atmosphere, 
resulting in a colour change from colorless to bright orange. The reaction mixture was stirred for 
30 min, and then tributyl borate (8.0 mL, 29.6 mmol) was added. After stirring the resulting 
solution at room temperature overnight, 5% HCl aqueous solution (20 mL) was added to redissolve 
the pale-yellow precipitate formed. The organic phase was then separated and extracted with an 
aqueous NaOH solution (1 M, 2 × 20 mL); the combined aqueous phase was acidified (HCl, 37%) 
under vigorous stirring until the apparition of an off-white precipitate. The product 3 was then 
filtered, washed with acidified water and dried under reduced pressure (3.3 g, 96%). 
1H NMR (400 MHz, DMSO-d6): δ = 2.36 (s, 3H, Me), 7.49 (s, 1H, thiophene), 8.32 (s, 2H, 
B(OH)2). MS (ESI): m/z = 220.9 [M]+ (expected: 220.94). 
4-Bromo-5-methyl-2-(4-pyridyl)thiophene (4). 4-Bromopyridine hydrochloride (1.3 g, 6.7 
mmol) and 3 (1.0 g, 4.5 mmol) were subsequently added under a nitrogen atmosphere to a solution 
of [Pd(PPh3)4] (260 mg, 5% mol) in anhydrous THF (20 mL) and 20% aqueous K2CO3 (20 mL). 
The resulting two-phase system was heated to 50 °C, stirred in the dark overnight and then cooled 
to room temperature before dichloromethane (25 mL) and water (15 mL) were added. The organic 
layer was separated, washed with brine (25 mL), dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude product was purified by column chromatography on silica gel 
with dichloromethane as the eluent, yielding the final product 4 as an off-white solid (0.94 g, 82%). 
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1H NMR (400 MHz, CDCl3): δ = 2.45 (s, 3H, Me), 7.32 (s, 1H, thiophene), 7.38 (m, 2H, J1 = 
6.0 Hz, J2 = 2.4 Hz, pyridine), 8.59 (m, 2H, J1 = 6.0 Hz, J2 = 2.4 Hz, pyridine). MS (ESI): m/z = 
254.0 [M]+ (expected: 253.96). 
4-Bromo-5-methyl-2-(3-quinolyl)thiophene (5). Compound 5 was prepared following the 
procedure described for compound 4, but using 3-bromoquinoline (0.9 mL, 6.7 mmol) instead of 
4-bromopyridine. The crude product was purified by column chromatography on silica gel with 
dichloromethane as the eluent, to yield the final product as an off-white solid (0.81 g, 59%). 
1H NMR (400 MHz, CDCl3): δ = 2.48 (s, 3H, Me), 7.31 (s, 1H, thiophene), 7.58 (m, 2H, 
quinoline), 7.71 (m, 2H, quinoline), 7.84 (d, 2H, J = 8.8 Hz, quinoline), 8.12 (d, 2H, J = 8.8 Hz, 
quinoline), 8.21 (d, 2H, J = 2.4 Hz, quinoline), 9.11 (d, 2H, J = 2.4 Hz, quinoline). MS (ESI): m/z 
= 306.0 [M+H]+ (expected: 305.97). 
1-(2-Methyl-5-chloro-3-thienyl)-2-(2-methyl-5-phenyl-3-thienyl)-cyclopentene (6). 2 (1.0 g, 
3.0 mmol) was dissolved in anhydrous THF (10 mL) under a nitrogen atmosphere and treated with 
n-buthyllithium (2.0 mL of a 1.6 M solution in hexane, 3.2 mmol) at room temperature. After 
stirring in the dark for about 45 min, tributyl borate (1.2 mL, 4.5 mmol) was added and the resulting 
bright orange solution was then stirred in the dark for 1 h; it was subsequently used for the Suzuki 
cross-coupling reaction. In the meantime, in a separate flask, [Pd(PPh3)4] (180 mg, 5% mol) and 
bromobenzene (0.4 mL, 3.75 mmol) were dissolved in a solvent mixture containing anhydrous 
THF (20 mL) and 20% aqueous K2CO3 solution (20 mL), under a dinitrogen atmosphere. This 
two-phase system was stirred at 50 °C for 15 min and the previous freshly prepared boronic 
derivative solution was added dropwise with a syringe. The resulting reaction mixture was stirred 
in the dark overnight, after which it was cooled to room temperature; dichloromethane (25 mL) 
and water (15 mL) were subsequently added. The organic layer was separated, washed with brine 
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(25 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product 
was purified by column chromatography on silica gel with a 19:1 mixture of cyclohexane and ethyl 
acetate as the eluent, yielding 6 as a slightly colored oil (0.74 g, 66%). 
1H NMR (400 MHz, CDCl3): δ = 1.88 (s, 3H, Me), 2.00 (s, 3H, Me), 2.05 (m, 2H, 7.6 Hz, 
cyclopentene), 2.75 (m, 2H, Japp = 7.6 Hz, cyclopentene), 2.81 (m, 2H, Japp = 7.6 Hz, 
cyclopentene), 6.62 (s, 1H, thiophene), 6.99 (s, 1H, thiophene), 7.23 (m, 1H, Japp = 7.2 Hz, phenyl), 
7.34 (m, 2H, Japp = 7.2 Hz, phenyl), 7.49 (m, 2H, Japp = 7.2 Hz, phenyl). MS (ESI): m/z = 371.1 
[M]+ (expected: 371.07). 
1,2-Bis(2-methyl-5-(4-pyridyl)-3-thienyl)cyclopentene (L1). Ligand L1, whose synthetic 
pathway was described earlier,1 was prepared as described below. This procedure was applied for 
all ligands including a central cyclopentene ring (Ligands L3, L5, L6 and L7). 
2 (1.0 g, 3.0 mmol) was dissolved in anhydrous THF (10 mL) under a nitrogen atmosphere and 
treated with n-buthyllithium (4.0 mL of a 1.6 M solution in hexane, 6.4 mmol) at room 
temperature. The reaction mixture was stirred in the dark for about 45 min until a light brown 
precipitate appeared, and tributyl borate (2.4 mL, 8.9 mmol) was added subsequently. The 
resulting bright orange solution was stirred in the dark for 1 h and subsequently used for a Suzuki 
cross-coupling reaction. Hence, in a separate flask, [Pd(PPh3)4] (360 mg, 5% mol) and 4-
bromopyridine hydrochloride (1.46 g, 7.5 mmol) were dissolved in a mixture of anhydrous THF 
(20 mL) and 20% aqueous solution of K2CO3 (20 mL) under a nitrogen atmosphere. This two-
phase system was stirred at 50 °C for 15 min and the previous freshly prepared solution of the 
boronic derivative of 2 was added dropwise with a syringe. The resulting reaction mixture was 
then stirred in the dark overnight, after which it was cooled to room temperature and treated with 
dichloromethane (25 mL) and water (15 mL). The organic layer was separated, washed with brine 
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(25 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product 
was purified by column chromatography on silica gel with ethyl acetate (containing 1% NH3) as 
the eluent, yielding the final product as a white solid (0.60 g, 48%). 
1H NMR (400 MHz, CDCl3): δ = 2.03 (s, 6H, Me), 2.11 (m, 2H, J = 7.6 Hz, cyclopentene), 2.85 
(t, 4H, J = 7.6 Hz, cyclopentene), 7.22 (s, 2H, thiophene), 7.35 (m, 4H, Japp = 6.4 Hz, pyridine), 
8.53 (m, 4H, Japp = 6.4 Hz, pyridine). 13C NMR (100 MHz, CDCl3): δ = 14.8, 23.1, 38.6, 119.4, 
126.4, 134.9, 136.8, 137.2, 137.4, 141.4, 150.4. MS (ESI): m/z = 415.1 [M+H]+ (expected: 
415.13). Elemental Analyses calculated for C25H22N2S2 (%): C 72.43, H 5.35, N 6.76, S 15.47; 
found: C 72.75, H 5.40, N 6.59, S 15.30. 
1,2-Bis(2-methyl-5-(4-pyridyl)-3-thienyl)perfluorocyclopentene (L2). Ligand L2, whose 
synthetic pathway was described earlier,1 was prepared as described below. This procedure was 
applied for the other ligand containing a central perfluorocyclopentene ring, namely L4. 
4 (1.0 g, 4.0 mmol) was suspended in anhydrous diethyl ether (15 mL) under a nitrogen 
atmosphere. Then, n-buthyllithium (2.6 mL of a 1.6 M solution in hexane, 4.2 mmol) was added 
dropwise at -78 °C. After stirring the resulting pink suspension for 30 min, octafluorocyclopentene 
(1.35 mL of a 20% solution in anhydrous Et2O, 2.0 mmol) was added and the ensuing reaction 
mixture was stirred for 1 h at -78 °C. The cooling bath was subsequently removed, and the stirring 
continued at room temperature for 3 h, after which dichloromethane (25 mL) and water (25 mL) 
were added. The organic layer was separated, washed with brine (25 mL), dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by column 
chromatography on silica gel using ethyl acetate (containing 1% NH3) as the eluent, yielding L2 
as a pale brown solid (0.27 g, 26%). The low yield may be due to the fact that 
octafluorocyclopentene is highly volatile (B.p. = 27 ºC). 
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1H NMR (400 MHz, CDCl3): δ = 2.00 (s, 6H, Me), 7.41 (m, 4H, J1 = 4.4 Hz, J2 = 1.6 Hz, 
pyridine), 7.47 (s, 2H, thiophene), 8.61 (m, 4H, J1 = 4.4 Hz, J2 = 1.6 Hz, pyridine). 19F NMR (400 
MHz, CDCl3): δ = -131.81 (quint, 2H, J = 5.6 Hz), -110.11 (t, 4H, J = 5.6 Hz). 13C NMR (100 
MHz, CDCl3): δ = 14.9, 111.0 (multiplet), 116.1 (multiplet), 119.7, 124.8, 126.3, 136.3 (multiplet), 
139.5, 140.3, 143.8, 150.7. MS (ESI): m/z = 523.1 [M+H]+ (expected: 523.07). Elemental 
Analyses calculated for C25H16F6N2S2 (%): C 57.47, H 3.09, N 5.36, S 12.27; found: C 58.14, H 
3.43, N 5.42, S 12.14. 
1,2-Bis(2-methyl-5-(3-quinolyl)-3-thienyl)cyclopentane (L3). L3 was prepared following the 
procedure described for L1, but using 3-bromoquinoline (1.0 mL, 7.5 mmol) as the bromide 
derivative in the Suzuki cross-coupling reaction. The crude product was then purified by column 
chromatography on silica gel with a 4:1 mixture of dichloromethane and ethyl acetate as the eluent, 
producing L3 as a bright white solid (0.87 g, 56%). 
1H NMR (400 MHz, CDCl3): δ = 2.10 (s, 6H, Me), 2.15 (m, 2H, J = 7.6 Hz, cyclopentene), 2.91 
(t, 4H, J = 7.6 Hz, cyclopentene), 7.23 (s, 2H, thiophene), 7.53 (m, 2H, J1 = 6.8 Hz, J2 = 1.2 Hz, 
quinoline), 7.66 (m, 2H, J1 = 6.8 Hz, J2 = 1.2 Hz, quinoline), 7.79 (d, 2H, J = 8.0 Hz, quinoline), 
8.07 (d, 2H, J = 8.0 Hz, quinoline), 8.14 (d, 2H, J = 2.0 Hz, quinoline), 9.09 (d, 2H, J = 2.0 Hz, 
quinoline). 13C NMR (100 MHz, CDCl3): δ = 14.7, 23.2, 38.6, 125.5, 127.3, 127.7, 127.9, 128.1, 
129.2, 129.4, 130.6, 135.0, 136.1, 136.4, 137.2, 147.2, 148.4. MS (ESI): m/z = 516.1 [M]+ 
(expected: 516.17). Elemental Analyses calculated for C33H26N2S2 (%): C 77.01, H 5.09, N 5.44, 
S 12.46; found: C 76.73, H 5.22, N 5.59, S 12.29. 
1,2-Bis(2-methyl-5-(3-quinolyl)-3-thienyl)perfluorocyclopentene (L4). 5 (1.2 g, 4.0 mmol) 
was suspended in anhydrous THF (15 mL) under a nitrogen atmosphere. Next, n-buthyllithium 
(2.6 mL of a 1.6 M solution in hexane, 4.2 mmol) was added dropwise at -78 °C.After stirring the 
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resulting pink suspension for 30 min, octafluorocyclopentene (1.35 mL of a 20% solution in 
anhydrous THF, 2.0 mmol) was added and the reaction mixture was stirred for 1 h at -78 °C. 
Afterwards, the cooling bath was removed and the stirring continued at room temperature for 3 h, 
after which dichloromethane (25 mL) and water (25 mL) were added. The organic layer was 
separated, washed with brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel using ethyl 
acetate as the eluent, yielding L4 as a pale blue solid (0.18 g, 14%). 
1H NMR (400 MHz, CDCl3): δ = 2.08 (s, 6H, Me), 7.47 (s, 2H, thiophene), 7.58 (m, 2H, 
quinoline), 7.72 (m, 2H, quinoline), 7.84 (d, 2H, J = 8.0 Hz, quinoline), 8.11 (d, 2H, J = 8.0 Hz, 
quinoline), 8.24 (br, 2H, quinoline), 9.12 (d, 2H, J = 2.0 Hz, quinoline). 19F NMR (400 MHz, 
CDCl3): δ = -131.82 (quint, 2H, J = 5.6 Hz), -109.97 (t, 4H, J = 5.6 Hz). 13C NMR (100 MHz, 
CDCl3): δ = 14.8, 111.1 (multiplet), 116.2 (multiplet), 123.9, 126.3, 126.5, 127.6, 127.9, 128.0, 
129.4, 129.9, 131.5, 136.4 (multiplet), 139.0, 142.7, 147.5, 148.1. MS (ESI): m/z = 623.1 [M]+ 
(expected: 623.1). Elemental Analyses calculated for C33H20F6N2S2 (%): C 63.66, H 3.24, N 4.50, 
S 10.30; found: C 63.59, H 3.70, N 4.47, S 9.76. 
1,2-Bis(2-methyl-5-(5-methyl-3-pyridyl)-3-thienyl)cyclopentene (L5). L5 was prepared 
following the procedure described for L1 but using 3-bromo-5-methylpyridine (0.85 mL, 7.5 
mmol) as the bromide derivative in the Suzuki cross-coupling reaction. The crude product was 
then purified by column chromatography on silica gel with a 3:1 mixture of ethyl acetate and 
dichloromethane as the eluent to yield the L5 as a white solid (0.69 g, 52%). 
1H NMR (400 MHz, CDCl3): δ = 2.02 (s, 6H, Me), 2.10 (m, 2H, J = 7.6 Hz, cyclopentene), 2.34 
(s, 6H, Me), 2.85 (t, 4H, J = 7.6 Hz, cyclopentene), 7.05 (s, 2H, thiophene), 7.55 (s, 2H, pyridine), 
8.29 (s, 2H, pyridine), 8.56 (s, 2H, pyridine). 13C NMR (100 MHz, CDCl3): δ = 14.6, 18.5, 23.2, 
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38.6, 125.1, 130.0, 133.0, 133.2, 134.9, 135.7, 136.1, 137.0, 143.9, 148.7. MS (ESI): m/z = 444.1 
[M]+ (expected: 444.17). Elemental Analyses calculated for C27H28N2S2 (%): C 73.26, H 5.92, N 
6.33, S 14.49; found: C 72.31, H 6.17, N 6.33, S 14.09. 
1,2-Bis(2-methyl-5-(1-methyl-1H-imidazol-2-yl)-3-thienyl)cyclopentane (L6). L6 was 
prepared following the procedure described for L1 but using 2-bromo-1-methyl-1H-imidazole (1.0 
g, 6.2 mmol) as the bromide derivative in the Suzuki cross-coupling reaction. The crude product 
was then purified by column chromatography on silica gel with ethyl acetate (containing 1% NH3) 
as the eluent, to yield L6 as a slightly pink solid (0.47 g, 37%). 
1H NMR (400 MHz, CDCl3): δ = 2.08 (m, 2H, J = 7.6 Hz, cyclopentene), 2.10 (s, 6H, Me), 2.83 
(t, 4H, J = 7.6 Hz, cyclopentene), 3.65 (s, 6H, N-Me), 6.84 (d, 2H, J = 1.2 Hz, imidazole), 6.96 (s, 
2H, thiophene), 7.01 (d, 2H, J = 1.2 Hz, imidazole). 13C NMR (100 MHz, CDCl3): δ = 14.4, 23.2, 
34.6, 38.2, 122.4, 126.9, 128.5, 128.9, 135.0, 136.2, 136.2, 142.4. MS (ESI): m/z = 422.1 [M]+ 
(expected: 422.16). Elemental Analyses calculated for C23H24N4S2 (%): C 65.68, H 5.75, N 13.32, 
S 15.25; found: C 65.38, H 6.07, N 13.21, S 15.43. 
1-(2-Methyl-5-(4-pyridiyl)-3-thienyl)-2-(2-methyl-5-phenyl-3-thienyl)-cyclopentene (L7). 6 
(0.7 g, 1.9 mmol) was dissolved in anhydrous THF (10 mL) under a dinitrogen atmosphere and 
treated with n-buthyllithium (1.3 mL of a 1.6 M solution in hexane, 2.1 mmol) at room 
temperature. After stirring in the dark for about 45 min, tributyl borate (0.8 mL, 3.0 mmol) was 
added and the resulting bright red solution was stirred in the dark for 1 h; it was subsequently used 
for the Suzuki cross-coupling reaction. Meanwhile, in a separate flask, [Pd(PPh3)4] (115 mg, 5% 
mol) and 4-bromopyridine hydrochloride (0.47 g, 2.4 mmol) were dissolved in a solvent mixture 
composed of anhydrous THF (20 mL) and 20% aqueous K2CO3 solution (20 mL) under a 
dinitrogen atmosphere. This two-phase system was stirred at 50 °C for 15 min and the previously 
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prepared boronic derivative solution was added dropwise with a syringe. The resulting reaction 
mixture was then stirred in the dark overnight, after which it was cooled to room temperature and 
dichloromethane (25 mL) and water (15 mL) were added. The organic layer was separated, washed 
with brine (25 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude product was purified by column chromatography on silica gel with ethyl acetate as the eluent, 
yielding L7 as a brown solid (0.57 g, 72%). 
1H NMR (400 MHz, CDCl3): δ = 1.99 (s, 3H, Me), 2.04 (s, 3H, Me), 2.05-2.14 (m, 2H, Japp = 
7.6 Hz, cyclopentene), 2.85 (t, 4H, J = 7.4 Hz, cyclopentene), 7.02 (s, 1H, thiophene), 7.20-7.25 
(m, 2H, thiophene + phenyl), 7.31-7.36 (m, 4H, phenyl + pyridine), 7.48-7.51 (m, 2H, Japp = 8.4 
Hz, phenyl), 8.52 (dd, 2H, J = 1.5 Hz, J = 4.7 Hz, pyridine). 13C NMR (100 MHz, CDCl3): δ = 
14.6, 14.9, 23.2, 38.6, 38.6, 119.5, 124.0, 125.5, 126.9, 127.2, 129.0, 134.1, 134.5, 134.6, 135.7, 
136.3, 136.6, 137.6, 137.9, 140.1, 142.0, 149.9. MS (ESI): m/z = 413.1 [M]+ (expected: 413.13). 
[{trans-PtCl2(DMSO)}2(μ-L1)] (C1). cis-[PtCl2(DMSO)2]22 (211 mg, 0.5 mmol) was 
suspended in methanol (40 mL), and the system was refluxed until the complex was completely 
dissolved. After hot filtering the resulting yellow solution to remove any Pt(0) impurities, ligand 
L1 (104 mg, 0.25 mmol) was immediately added and the mixture was stirred in the dark at room 
temperature overnight, yielding C1 as a pale-green solid, which was filtered, washed with 
methanol and dried under reduced pressure (260 mg, 94%). 
1H NMR (400 MHz, CDCl3): δ = 2.03 (s, 6H, Me), 2.13 (m, 2H, J = 7.6 Hz, cyclopentene), 2.85 
(t, 4H, J = 7.6 Hz, cyclopentene), 3.47 (s, 12H, DMSO), 7.28 (s, 2H, thiophene), 7.39 (m, 4H, Japp 
= 6.4 Hz, pyridine), 8.59 (m, 4H, Japp = 6.4 Hz, pyridine). 13C NMR (100 MHz, CDCl3): δ = 15.0, 
23.0, 38.6, 44.3, 120.5, 128.9, 134.5, 135.1, 137.9, 140.8, 144.5, 151.7. MS (ESI): m/z = 1124.9 
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[M+Na]+ (expected: 1124.94). Elemental Analyses calculated for C29H34Cl4N2O2Pt2S4 (%): C 
31.58, H 3.11, N 2.54, S 11.63; found: C 31.11, H 3.09, N 2.52, S 11.53. 
[{trans-PtCl2(DMSO)}2(μ-L2)] (C2). Complex C2 was prepared following the procedure 
described for the synthesis of C1, but using ligand L2 (136 mg, 0.25 mmol) to obtain the 
corresponding product as an off-white solid (295 mg, 95%). 
1H NMR (400 MHz, CDCl3): δ = 2.03 (s, 6H, Me), 3.48 (s, 12H, DMSO), 7.50 (m, 4H, J1 = 5.6 
Hz, J2 = 1.6 Hz, pyridine), 7.55 (s, 2H, thiophene), 8.71 (m, 4H, J1 = 5.6 Hz, J2 = 1.6 Hz, pyridine). 
19F NMR (400 MHz, CDCl3): δ = -131.78 (quint, 2H, J = 5.6 Hz), -110.10 (t, 4H, J = 5.6 Hz). 13C 
NMR (100 MHz, CDCl3): δ = 15.1, 44.4, 121.0, 126.8, 127.3, 137.0, 143.4, 146.5, 152.3. MS 
(ESI): m/z = 1231.9 [M+Na]+ (expected: 1231.88). Elemental Analyses calculated for 
C29H28Cl4F6N2O2Pt2S4 (%): C 28.77, H 2.33, N 2.31, S 10.59; found: C 29.01, H 2.30, N 2.48, S 
10.36. 
[{trans-PtCl2(DMSO)}2(μ-L3)] (C3). Complex C3 was prepared following the procedure 
described for the synthesis of C1 but using ligand L3 (129 mg, 0.25 mmol) to obtain the 
corresponding product as a pale-green solid (255 mg, 85%). 
1H NMR (400 MHz, CDCl3): δ = 2.09 (s, 6H, Me), 2.17 (m, 2H, J = 7.6 Hz, cyclopentene), 2.93 
(t, 4H, J = 7.6 Hz, cyclopentene), 3.47 (s, 12H, DMSO), 7.30 (s, 2H, thiophene), 7.65 (m, 2H, Japp 
= 7.6 Hz, quinoline), 7.82-7.88 (m, 4H, quinoline), 8.29 (d, 2H, J = 2.0 Hz, quinoline), 9.25 (d, 
2H, J = 2.0 Hz, quinoline), 9.30 (d, 2H, J = 8.8 Hz, quinoline). 13C NMR (100 MHz, CDCl3): δ = 
14.9, 23.3, 38.7, 43.9, 126.8, 128.3, 128.5, 128.9, 129.2, 129.9, 131.1, 133.7, 134.2, 135.1, 137.6, 
137.7, 144.5, 151.5. MS (ESI): m/z = 1225.0 [M+Na]+ (expected: 1224.97). Elemental Analyses 
calculated for C37H38Cl4N2O2Pt2S4 (%): C 36.94, H 3.18, N 2.33, S 10.66; found: C 36.44, H 3.18, 
N 2.35, S 10.11. 
 18 
Single crystals of complex C3, suitable for X-ray diffraction studies, were obtained by slow 
diffusion of diethyl ether into a concentrated solution of the complex in dichloromethane. 
[{trans-PtCl2(DMSO)}2(μ-L4)] (C4). Complex C4 was prepared following the procedure 
described for the synthesis of C1, but using ligand L4 (156 mg, 0.25 mmol) to obtain the 
corresponding product as an off-white solid (260 mg, 79%). 
1H NMR (400 MHz, CDCl3): δ = 2.12 (s, 6H, Me), 3.52 (s, 12H, DMSO), 7.51 (s, 2H, thiophene), 
7.71 (m, 2H, Japp = 7.6 Hz, quinoline), 7.89-7.93 (m, 4H, quinoline), 8.39 (d, 2H, J = 2.0 Hz, 
quinoline), 9.27 (d, 2H, J = 2.0 Hz, quinoline), 9.37 (d, 2H, J = 9.2 Hz, quinoline). 19F NMR (400 
MHz, CDCl3): δ = -131.84 (quint, 2H, J = 5.6 Hz), -109.87 (t, 4H, J = 5.6 Hz). 13C NMR (100 
MHz, CDCl3): δ = 15.1, 44.0, 125.3, 126.5, 127.9, 128.4, 128.7, 129.3, 129.7, 131.8, 135.1, 136.3, 
144.2, 145.0, 151.3. MS (ESI): m/z = 1332.9 [M+Na]+ (expected: 1332.92). Elemental Analyses 
calculated for C37H32Cl4F6N2O2Pt2S4 (%): C 33.90, H 2.46, N 2.14, S 9.78; found: C 33.86, H 2.47, 
N 2.33, S 9.64. 
Single crystals of complex C4, suitable for X-ray diffraction studies, were obtained by slow 
diffusion of diethyl ether into a concentrated solution of the complex in dichloromethane. 
[{trans-PtCl2(DMSO)}2(μ-L5)] (C5). Complex C5 was prepared following the procedure 
described for the synthesis of C1, but using ligand L5 (111 mg, 0.25 mmol) to obtain the 
corresponding product as an off-white solid (235 mg, 83%). 
1H NMR (400 MHz, CDCl3): δ = 2.02 (s, 6H, Me), 2.11 (m, 2H, J = 7.6 Hz, cyclopentene), 2.38 
(s, 6H, Me), 2.84 (t, 4H, J = 7.6 Hz, cyclopentene), 3.46 (s, 12H, DMSO), 7.10 (s, 2H, thiophene), 
7.66 (s, 2H, pyridine), 8.35 (s, 2H, pyridine), 8.66 (d, 2H, J = 1.6 Hz, pyridine). 13C NMR (100 
MHz, CDCl3): δ = 13.6, 17.5, 22.0, 37.4, 43.2, 125.5, 131.3, 132.2, 133.9, 134.8, 135.1, 136.2, 
136.5, 144.7, 148.4. MS (ESI): m/z = 1154.0 [M + Na]+ (expected: 1153.97). Elemental Analyses 
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calculated for C31H38Cl4N2O2Pt2S4 (%): C 32.93, H 3.39, N 2.48, S 11.34; found: C 33.03, H 3.64, 
N 2.62, S 11.12. 
[{trans-PtCl2(DMSO)}2(μ-L6)] (C6). Complex C6 was prepared following the procedure 
described for the synthesis of C1, but using ligand L6 (105 mg, 0.25 mmol) to obtain the 
corresponding product as an off-white solid (205 mg, 74%). 
1H NMR (400 MHz, CDCl3): δ = 2.12 (m, 2H, cyclopentene), 2.23 (s, 6H, Me), 2.89 (t, 4H, 
cyclopentene), 3.33 (s, 12H, DMSO), 3.68 (s, 6H, N-Me), 6.95 (d, 2H, J = 1.2 Hz, imidazole), 
7.15 (d, 2H, J = 1.2 Hz, imidazole), 7.25 (s, 2H, thiophene). 13C NMR (100 MHz, CDCl3): δ = 
14.9, 23.2, 36.0, 38.4, 44.1, 123.1, 123.3, 128.4, 132.5, 134.9, 135.9, 139.8, 142.3. MS (ESI): m/z 
= 1108 [M]+ (expected: 1107.97). Elemental Analyses calculated for C27H36Cl4N4O2Pt2S4 (%): C 
29.25, H 3.27, N 5.05, S 11.57; found: C 29.21, H 3.37, N 5.04, S 11.69. 
trans-[PtCl2(DMSO)(L7)] (C7). Complex C7 was prepared following the procedure described 
for the synthesis of C1 but using equimolar amounts of cis-[PtCl2(DMSO)2] (105 mg, 0.25 mmol) 
and ligand L7 (103 mg, 0.25 mmol) to obtain the corresponding mononuclear product as a dark 
green solid (80 mg, 42%). 
1H NMR (400 MHz, CDCl3): δ = 1.97 (s, 3H, Me), 2.07 (s, 3H, Me), 2.11 (m, 2H, 7.6 Hz, 
cyclopentene), 2.84 (m, 4H, cyclopentene), 3.47 (s, 6H, DMSO), 6.99 (s, 1H, thiophene), 7.24 (m, 
1H, J1 = 7.6 Hz, J2 = 1.2 Hz, phenyl), 7.31 (s, 1H, thiophene), 7.34 (m, 2H, Japp = 7.6 Hz, phenyl), 
7.39 (m, 2H, J1 = 5.6 Hz, J2 = 1.6 Hz, pyridine), 7.48 (m, 2H, Japp = 7.6 Hz, phenyl), 8.56 (m, 2H, 
J1 = 5.6 Hz, J2 = 1.6 Hz, pyridine). 13C NMR (100 MHz, CDCl3): δ = 14.5, 15.1, 23.1, 38.4, 38.6, 
44.3, 120.5, 123.8, 125.4, 127.3, 129.0, 129.3, 133.5, 134.0, 134.3, 134.6, 136.3, 136.5, 138.4, 
140.3, 141.0, 144.8, 151.7. MS (ESI): m/z = 780.0 [M + Na]+ (expected: 780.03). Elemental 
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Analyses calculated for C28H29Cl2NOPtS3 (%): C 44.38, H 3.86, N 1.85, S 12.69; found: C 43.28, 
H 3.94, N 2.04, S 12.46. 
X-ray structure determination. Data for the open and closed forms of complex C3 and the 
open form of complex C4 were collected on a Bruker PHOTON100 CMOS diffractometer at 
beamline 11.3.1 of the Advanced Light Source (synchrotron radiation, λ = 0.7749 Å), respectively 
on a dark purple/orange (depending on crystal orientation) plate at 200 K and a colourless plate at 
100 K. Data reduction was done with SAINT.23 The structures were solved by intrinsic phasing 
using SHELXT,24 and refined by full-matrix least squares on F2 with SHELXL-2014.25 Absorption 
corrections for the structure of C4 were done with SADABS.23 The crystal of C3 was found to 
contain both the open and closed forms. It is unclear if this is a consequence of co-crystallization 
or solid-state transformation upon exposure to light. The structure was refined as a 2-component 
twin using cells and twin law determined with CELL_NOW.26 Absorption corrections were done 
with TWINABS.26 The heavy disorder of the central part of the ligand associated with the presence 
of both photoisomers in the same crystal, initially defined from electron-density peaks, was refined 
with both 1,2- and 1,3- distances and displacement parameters restraints. Crystallographic and 
refinement parameters are summarized in Tables S1 and S3, for complexes C3 and C4, 
respectively (ESI†). All details can be found in CCDC 1565000 (C3) and 1565001 (C4) that 
contain the supplementary crystallographic data for this paper. These data can be obtained free of 
charge from the Cambridge Crystallographic Data Center via 
https://summary.ccdc.cam.ac.uk/structure-summary-form. 
Agarose gel electrophoresis. 20 μL of cacodylate-buffered solutions containing 15 μM (in base 
pair) pBR322 plasmid DNA, 0.5-2.0 equivalents of the complexes (7.5-30 μM) and 5% DMSO 
were incubated in the dark for 24 h at 37 °C. Analogous sample solutions of free plasmid DNA 
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and DNA bound to cisplatin (0.5 equiv., without DMSO) were also prepared and used as controls. 
After the incubation, all samples were treated with 4 μL of a xylene cyanol 1x aqueous solution 
(containing 30% glycerol) and subsequently electrophoretized in agarose gel (1% in TAE buffer, 
Tris-Acetate-EDTA) for 1 h at 6.25 V cm─1, using a Bio-Rad horizontal tank connected to a 
Consort EV231 variable potential power supply. Next, the gel was treated with SYBR Safe DNA 
gel stain and subsequently photographed with a Bio-Rad Gel Doc EZ imager. 
Ethidium bromide displacement assays. Samples containing 15 μM (in base pair) ct-DNA and 
75 μM ethidium bromide in cacodylate buffer were incubated for 1 h at 37 °C, after which they 
were treated with increasing amounts of the complex stock solutions (see Materials and methods). 
The resulting samples, containing 1-25 μM of the studied complexes and up to a 5% DMSO in a 
final volume of 3 mL, were then incubated in the dark for 24 h at 37 °C. Following the incubation, 
the fluorescence emission spectra of all samples were recorded at room temperature in the range 
530-800 nm, using a Horiba Jovin Yvon SPEX Fluorolog 3-22 spectrofluorometer and applying 
an excitation wavelength of λexc = 514 nm. Cacodylate-buffered solutions of ct-DNA/EB (i.e. 
without complex) were used as control references. 
Circular dichroism spectroscopy. Samples containing 50 μM ct-DNA (in base pair), 5-25 μM 
of the studied complexes and up to 5% DMSO in a final volume of 3 mL of cacodylate-buffered 
solution were incubated for 24 h at 37 °C. Following the incubation, the circular dichroism spectra 
of all samples were recorded at room temperature using a Jasco J-815 CD spectropolarimeter. A 
wavelength range of 235-315 nm was used to minimize DMSO interference, using a bandwidth of 
2 nm, a data pitch of 0.5 nm, scanning speed of 50 nm min─1, response time of 1 s and 4 
accumulations. Cacodylate-buffered solutions of ct-DNA were used as control references. 
 22 
Cell lines and culture. Human lung adenocarcinoma (A549), melanoma (A375), breast 
adenocarcinoma (MCF7), colorectal adenocarcinoma (SW620) and ovarian adenocarcinoma 
(SKOV3) cell lines used in this study were purchased from the American Type Culture Collection 
(ATCC). All cell lines were tested and authenticated by ATCC using short tandem repeat analysis 
and were cultured (passage number 10-25) following ATCC recommended media. A549, A375, 
SW620 and SKOV3 cells were cultured in DMEM medium supplemented with 10% (v/v) fetal 
bovine serum (FBS), 100 unit/mL penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine. 
MCF7 cells were cultured in DMEM-F12 (Ham) media (1:1) supplemented with 5% horse serum 
(v/v), 100 μM sodium pyruvate, 10 μg/mL insulin, 100 unit/mL penicillin, 100 μg/mL 
streptomycin and 2 mM L-glutamine. All cell lines were grown at 37 °C under a 5% CO2 
atmosphere. The cell lines were routinely tested using a specific standard PCR to control 
mycoplasma contamination. 
Cell viability assays. Cell proliferation was evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT) assay. Cells were plated in 96-well sterile plates at a density 
of 105 cells per mL (100 μL) and allowed to grow for 24 h. After attachment to the surface, the 
cells were then incubated with various concentrations of the studied complexes (10 and 50 μM for 
single-point experiments and within the range 0.5-5 μM for dose-response curves), freshly 
dissolved in DMSO and diluted in the corresponding culture medium (DMSO final concentration 
= 1%), for 48 h at 37 °C. Control cells were cultured in the corresponding culture medium plus the 
carrier (DMSO final concentration = 1%). Following the treatment, 10 μM MTT was added to 
each well for an additional 4 h. Afterwards, the medium was aspirated, the purple formazan 
precipitate was dissolved in 100 μL of DMSO, and the absorbance at 570 nm was measured in a 
multi-well plate reader Multiskan FC (Thermo Scientific). The cell viability was expressed as 
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percentage values with respect to control cells, and the data are shown as the mean value ± SD of 
three independent experiments. Dose-response curves and the corresponding IC50 values were 
obtained by means of non-linear regression (curve fit), calculated with the GraphPad Prism 5.0 
software. For comparison purposes, the cytotoxic effect of cisplatin was also evaluated under 
identical experimental conditions. 
 
RESULTS AND DISCUSSION 
 
Preparation of the ligands and their respective platinum(II) complexes. The diarylethene-
based ligands were prepared using common synthetic procedures (Figure S1).1, 21, 27 Ligands L1, 
L3 and L5-L7 were obtained in moderate to good yields, ranging from 37% to 72%, by Suzuki 
cross-coupling reaction between the in situ-generated bis-boronic ester derivative of 1,2-bis(5-
chloro-2-methyl-3-thienyl)cyclopentane and the corresponding bromo(hetero)arene (see 
Experimental section).28 Ligands L2 and L4, containing a perfluorinated cyclopentene ring, were 
synthesized in low yields (26% and 14%, respectively), by reaction of octafluorocyclopentene with 
the corresponding bromo heteroarylthiophene (see Experimental details). 
The photoswitching abilities of the ligands can be assessed by UV-Vis and 1H NMR 
spectroscopies. For example, the colorless, open form of L1 exhibits intense absorption bands in 
the UV region of the spectrum (Figures S2). The absorption observed at λ = 322 nm corresponds 
to the HOMO→LUMO transition, which, according to the Woodward-Hoffman rules, is required 
for the photocyclization process to occur.29 UV Irradiation of open L1 gives rise to the 
development of an intense new absorption band in the visible region, i.e. at λ = 544 nm (Figures 
S2), as reflected by the deep purple color of the solution. It can be pointed out here that a 
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photostationary state (PSS) is reached, which corresponds to a final equilibrium situation of the 
photocyclization reaction; although complete photoconversion is rarely achieved, the PSS is 
assumed to represent the closed form of the molecule.30 Similar features were observed for all 
other ligands, except for ligand L6, which cannot undergo photocyclization; this distinctive 
behavior was investigated theoretically, and was ascribed to the presence of a non-photoreactive 
HOMO─2→LUMO transition with a higher computed oscillator strength value than that of the 
HOMO→LUMO one, therefore impeding the photocyclization process.31 The photochemical 
transformation of all ligands, except L6, can also be followed by 1H NMR. For instance, NMR 
spectra of L2 after different photoirradiation times are illustrated in Figure S3. These spectra are 
representative of the other compounds inspected in the present study (excluding L6 which does 
not cyclize). Upon UV exposure, a gradual disappearance of the original NMR signals (open form 
of L2) is observed, which is accompanied by the concomitant, progressive apparition of a new set 
of peaks ascribed to closed L2 (see blue asterisks in Figure S3). The upfield shift of the proton at 
the 4-position of the thiophene, from 7.47 to 6.85 ppm, corroborates the occurrence of the expected 
electrocyclic reaction, generating a new intramolecular bond at the proximal 2-position. For 
irradiation times longer than 5 minutes, no further variation of the peaks was noticed, therefore 
indicating that the PPS was reached. At this equilibrium situation, a photoconversion ratio of 0.86 
could be determined from the relative intensity of the two sets of signals (i.e. from the open and 
closed forms of L2). Comparable features are observed for ligands L1, L3-L5 and L7. 
After full characterization, platination of the ligands was carried out, generating complexes C1-
C7 with good yields, from 42% to 95% (Figure 1). Hence, reaction of two equivalents of cis-
[PtCl2(DMSO)2] (cis-dichlorobis(dimethyl sulfoxide)platinum(II)) with one equivalent of L1-L6 
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produced the corresponding complexes C1-C6, while the reaction between one equivalent of the 
platinum(II) salt and one equivalent of L7 yielded C7. 
Single crystals, suitable for X-ray diffraction studies, could be obtained for C2, C3, C4 and C6. 
The crystal structures of C21 and C631 were described earlier. The X-ray structures of C3 and C4 
are reported herein. Crystallographic and refinement parameters are summarized in Tables S1 and 
S3 for C3 and C4, respectively (ESI†), and selected coordination bond lengths and angles for C3 
are listed in Table S2 (ESI†), whereas those for C4 are shown in Table S4 (ESI†). The molecular 
structures of C3 and C4 (Figures S4 and S5) are related to those of C2 and C6. In all cases, the 
platinum atom is in a square-planar environment defined by two trans chlorido ligands, an S-
coordinated DMSO solvent molecule and a nitrogen atom from the heteroaromatic moiety of the 
ligand. It can be pointed out here that the solid-state structure of C3 contains both the open and 
closed forms of the metal complex, in a 31.6/68.4 (Figure S4), which is not commonly observed 
with such photoswitching molecules. 
It can also be stressed that all complexes contain a DMSO, which is trans to the N-coordinated 
ligand (strong trans effect of S-coordinated DMSO32, 33); in principle, this solvent molecule may 
be used to further functionalize the platinum compounds,34 hence increasing the versatility of the 
system (since numerous monodentate ligands may be used to replace this DMSO). Moreover, one 
may expect that the high chloride concentration in blood (95-105 mM) would convert the 
compounds into more hydrophilic “[PtLCl3]‒” species (for instance a complex of the type 
[PtCl2(DMSO)L], where L is phosphane ligand, was reported that could convert into [PtCl3L]− in 
the presence of NBu4Cl35), which could be hydrolyzed inside cells (with subsequent DNA 
binding). 
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Agarose gel electrophoresis. After full characterization of complexes C1-C7, the interaction of 
their open and closed photoisomers with pBR322 DNA was investigated. The corresponding gel 
images are depicted in Figure 2. It can be mentioned here that one may expect that complexes C1-
C7 will exhibit a mechanism of action related to that of cisplatin. Hence, hydrolysis of the chlorides 
of C1-C7 should lead to the formation of aquated species,36, 37 which will bind to DNA by 
substitution of the water molecules for purine bases.38 Due to the trans-disposition of the chlorides, 
it is expected that each platinum ion will mostly produce 3-intrastand cross-links and 
monofunctional adducts, which will undergo conversion to interstrand cross-links;39 the diplatinum 
complexes should therefore show strong DNA interactions. It can be pointed out that polynuclear 
platinum complexes (PPCs) have shown remarkable biological activities.40 Furthermore, one may 
anticipate that the photo-induced closing/opening of the ligand will alter the DNA-binding 
properties of the corresponding complex isomers. Indeed, the electronic changes taking place upon 
ring closure will affect the hydrolysis of the chlorido ligands (and therefore their DNA-binding 
aptitude), and the change of flexibility between the closed and open species will modify their DNA 
binding; for instance, interstrand binding may be less favorable for the closed, more rigid 
complexes. 
As a matter of fact, for complexes C1-C5, a clearly distinct DNA-interacting behavior of the 
two isomeric forms is observed. At low concentration, open C1 appears to produce a decrease of 
the electrophoretic mobility of supercoiled DNA (lane 3), which may be explained by the 
unwinding of the double helix. However, this effect becomes less pronounced with the increase of 
the concentration of open C1 (lanes 4 to 6). In contrast to lane 3, DNA form I is detected in lanes 
4-6, and the diminution of its mobility with the increase of [open C1] resembles that of supercoiled 
DNA treated with cisplatin (lane 2).41, 42 This concentration-dependent interaction of open C1 with 
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DNA suggests that it exhibits different binding modes, most likely arising from cooperative effects 
between the platinum centers and the organic ligand. It seems that with only 0.5 equiv of open C1, 
non-covalent interactions play a role (lane 3), whereas for [open C1] ≥ 1 equiv, typical platination 
effects are taking place (lanes 4 to 6). 
 
 
Figure 2. Agarose gel electrophoresis images for pBR322 DNA incubated for 24 h at 37 °C with 
increasing quantities of the open and closed forms of complexes C1─C7 (solely the open form in 
the case of photoinactive C6). Lane 1: native plasmid DNA; lane 2: DNA + 0.5 equiv. of cisplatin; 
lanes 3─6: DNA + 0.5 to 2.0 equiv. of the open complex; lanes 7─10: DNA + 0.5 to 2.0 equiv. of 
the closed complex. 
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On the contrary, closed C1 behaves as a strong DNA intercalator (lanes 7 to 10), probably as the 
result of its higher planarity and electronic conjugation. It is well known that DNA intercalation 
induces a stronger local unwinding of the double helix than covalent binding; this may result in 
the relaxation of negatively supercoiled DNA sequences until reaching an open circular 
conformation, whereas further addition of the intercalating agent will lead to positive 
supercoiling.43 Such phenomenon is clearly occurring with closed C1 (lanes 7 to 10). At lane 7, an 
initial decrease of the mobility is observed, as the result of a partial twist reduction of the 
biomolecule. Upon increasing the amount of closed C1, this effect is enhanced, so that all initial 
DNA form I is relaxed and co-migrates with DNA form II (lane 8). Upon further increase of [closed 
C1], the DNA mobility is improved (lanes 9 and 10), which is likely due to a subsequent induction 
of positive supercoiling to the previously relaxed structure (lane 8). Finally, it should be noted that 
a vanishing of the band intensities takes place when the amount of closed C1 is increased (lanes 8 
to 10). This feature points to the precipitation of highly platinated DNA species. 
Replacement of the cyplopentene ring by a perfluorocyclopentene one (from C1 to C2) clearly 
modifies the DNA-interacting properties of the resulting complex. Like open C1, open C2 also 
induces the unwinding of DNA, the total conversion to form II now being observed for the highest 
complex concentration (lane 6). This feature may be explained by single-strand cleavage of the 
plasmid upon platinum binding, producing the complete relaxation of supercoiled DNA fragments 
through free rotation around the nicked strand. 
On the other hand, closed C2 exhibits intercalating properties as closed C1, but higher 
concentrations are required to give the same effect. Indeed, 1.0 equivalent of closed C1 is sufficient 
to provoke complete relaxation of supercoiled circular DNA (lane 8), whereas 2.0 equivalents are 
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required with closed C2 (lane 10). This weaker intercalating behavior exhibited by closed C2 may 
be due to repulsive interactions between the fluorine atoms of ligand L2 and the phosphate 
backbone. 
For complexes C3 and C4, minor differences were observed between their open and closed 
forms (Figure 2). In all cases, the treatment of plasmid DNA with increasing quantities of the two 
photoisomers of each compound gives rise to a noticeable decrease of the electrophoretic mobility 
of supercoiled DNA; the open and closed forms of C3 are even capable of inducing the co-
migration of supercoiled and open circular DNA (lanes 4-6 and lanes 8-10). The analogous 
activities of both forms of the complexes may be attributed to the larger, planar quinoline moieties 
of ligands L3 and L4, compared to the pyridine rings in L1 and L2, which apparently confers a 
comparable intercalating behavior to the photoisomers. It can also be noticed that C4 is less active 
than C3, confirming the negative influence of the fluorinated backbone of ligand L4 on the DNA 
interaction. 
Open C5 follows a dose-dependent pattern that is like that of open C1 (lanes 3-6). 0.5 equivalents 
of open C5 produce the complete unwinding of supercoiled circular DNA, generating its form II 
(lane 3). Higher amounts of open C5 induce effects that are comparable to those observed with 
cisplatin, therefore suggesting metal binding to DNA.  
Closed C5 exhibits the same behavior as its open form (see lanes 3-6 and lanes 7-10 in Figure 
2). Thus, closed C5 does not seem to show the intercalative properties observed with the closed 
isomers of the previous complexes (see above). This feature may arise from (i) steric hindrance 
caused by the methyl substituents of the pyridine ring of ligand L5 and/or (ii) the relative 
disposition of the metal centers (meta position instead of para position for the previous 
complexes). This drastic alteration of the DNA-interacting properties of closed C5 (compared for 
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instance to those of closed C1 and C2), triggered by a subtle modification of the metal-
coordinating unit, again indicates that the binding activity of the two photoisomers proceeds via 
two different mechanisms. 
As reported earlier, complex C6 does not display photoswitching properties.31 Consequently, 
only the DNA interaction of open C6 could be investigated. Hence open C6 behaves as open C1; 
namely, 0.5 equivalents of the complex lead to the formation of DNA form II (lane 3). Higher 
[open C6] result in effects comparable with those of the interaction of cisplatin with DNA, i.e. 
metal binding to the biomolecule. Actually, this covalent binding of open C6 appears to be 
particularly strong, since a vanishing of the bands is observed with the increase of its concentration 
(lanes 5-6), which is indicative of the precipitation of the resulting complex-DNA adducts. 
The mononuclear complex C7 has completely distinct behavior. No photoisomeric 
differentiation is observed; in both cases, a comparable retardation of the DNA mobility takes 
place (lanes 3-6 and lanes 7-10). Surprisingly, closed C7 does not exhibit better DNA-intercalating 
properties than open C7, even though one may have expected that substitution of one of the metal-
binding units by a phenyl ring (ligand L1 to ligand L7) would have somewhat favored the insertion 
of closed C7 between DNA base pairs. Consequently, it can be inferred that the strong DNA-
unwinding ability displayed by most closed complexes of the present study is due to not only their 
insertion between DNA base pairs, but also to the subsequent binding of the two platinum atoms. 
Fluorescent intercalator displacement assays. Competitive binding studies were carried out 
subsequently, using ethidium bromide (EB) bound to ct-DNA and the open and closed forms of 
the complexes, as fluorescence quenchers (through the release of EB). Fluorescence spectra were 
therefore recorded at constant concentrations of ct-DNA and EB, respectively 15 μM and 75 μM), 
by adding increasing amounts of both photoisomers of the platinum(II) complexes, viz. in the 
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concentration range 1─25 μM. Representative fluorescence spectra for open and closed C1 are 
shown in Figure 3. In all cases, a decrease of the fluorescent emission of the DNA/EB adduct44 is 
observed, which is indicative of the displacement of the dye resulting from the interaction of the 
complex with the double helix. 
 
 
Figure 3. Fluorescent emission spectra of ct-DNA/EB samples ([DNA]bp = 15 μM, [EB] = 75 μM) 
treated with increasing quantities (1─25 μM) of open C1 (top) and closed C1 (bottom), registered 
after incubation for 24 h at 37 °C. 
 
It can be noticed that the quenching effect is clearly more pronounced for closed C1 than for 
open C1 (Figure 3), hence suggesting that the closed photoisomer has a higher capacity to expel 
DNA-bound EB, and thus confirming its better intercalating properties (see gel electrophoresis 
results).45  
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To properly compare the DNA affinity of all studied species, the fluorescence emission data 
obtained were used to determine the corresponding Stern-Volmer quenching constants (KSV) for 
intermolecular deactivations, by applying the Stern-Volmer equation (1):46 
 
𝐼𝐼0
𝐼𝐼
= 1 + 𝐾𝐾𝑆𝑆𝑆𝑆[𝑄𝑄]  (1) 
 
In this expression, I0 is the initial fluorescence intensity of the DNA/EB system, I represents the 
fluorescence emission intensity after the addition of a quencher, and Q is the quenching molecule, 
which is the metal complex in the present study. A plot of I0/I versus [complex] at the maximum 
emission wavelength (i.e. λmax = 610 nm) gives a straight line, whose slope is equal to KSV. 
Applying this procedure, Stern-Volmer constants of KSV = 6.6 ± 0.8 · 103 M─1 and KSV = 42.5 ± 
0.6 · 103 M─1 were determined for open and closed C1, respectively (Figure 4). 
Similar trends were observed for the open and closed photoisomers of all compounds 
investigated, whose respective Stern-Volmer constants are listed in Table 1. 
 
Table 1. Calculated Stern-Volmer quenching constants for the titration of ct-DNA/EB ([DNA]bp 
= 15 μM, [EB] = 75 μM) with the different complexes (open and closed forms), at λexc = 514 nm 
and λem = 610 nm. 
Complex KSV (103 M─1), open form KSV (103 M─1), closed form 
C1 6.6 ± 0.8 42.5 ± 0.6 
C2 4.8 ± 0.9 26.8 ± 0.9 
C3 13.7 ± 0.7 58.0 ± 3.0 
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C4 18.4 ± 0.7 45.0 ± 3.0 
C5 9.9 ± 0.4 37.4 ± 0.8 
C6a 17.1 ± 0.9 n/a 
C7 1.4 ± 0.3 21.7 ± 0.6 
a This complex does not undergo photocyclization. 
 
 
Figure 4. Plots of I0/I vs. [complex] for the titration of ct-DNA/EB samples ([DNA]bp = 15 μM, 
[EB] = 75 μM) treated with the open (red) and closed (blue) forms of C1 at λexc = 514 nm and λem 
= 610 nm. Experimental data points obtained in triplicate and linear fitting of the data. 
 
In all cases, a significantly higher KSV value was obtained for the closed isomer, hence 
corroborating their higher intercalative behavior. Thus, one may expect that the closed forms of 
the platinum(II) complexes will induce higher growth inhibitory effects than their open 
counterparts. It can also be noticed that lower quenching constants were systematically achieved 
for the fluorinated closed-ring species, compared with their corresponding non-halogenated 
analogues (see C1 and C2, and C3 and C4 in Table 1). These features agree with the data achieved 
by gel electrophoresis (see above) and confirm the negative effect of the fluorinated cyclopentane 
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ring on the intercalation of the corresponding coordination compounds. These differences may 
result from a slight destabilization of the DNA/complex adducts through electrostatic repulsion 
between the fluorine atoms and the negatively charged phosphate backbone of the double helix.47 
A noticeably reduced dye-displacement ability is exhibited by the mononuclear complex C7 (in 
its both forms, see Table 1). For instance, closed C7 shows a KSV value that is twice lower than 
that of closed C1. These results are in line with the earlier data obtained with plasmid DNA and 
confirm that the binding of dinuclear species like C1 to neighboring nucleobases (after the 
insertion of the compound between base pairs) is crucial regarding the stabilization of the resulting 
DNA/complex adducts. 
This new set of data again show that the closed form of the diplatinum complexes are inducing 
stronger alterations of the double-helix conformation than the open one, apparently through a 
combination of intercalative and covalent interactions. It may therefore be expected that such 
closed species can be more efficient in inhibiting gene expression and DNA-replication processes, 
which may be reflected by a higher antiproliferative efficiency. 
The results achieved with photoinert C6 requires some attention. As indicated by its KSV value 
(Table 1), this imidazolic species exhibits a far superior degree of interaction with DNA than open 
C1 and C2 (Table 1). Its dye-displacement activity is comparable or even greater than that of 
quinoline-containing complexes C3 and C4. Contrary to these two compounds, C6 does not have 
potentially intercalating structural motifs; hence, C6 can expel ethidium bromide through a 
different mode of action. Most likely, the binding of C6 strongly alters the conformation of the 
double helix. Local modifications of the secondary or tertiary structure of DNA, like those 
produced by 1,3-interstrand crosslinks, may indeed force the dye to leave the nearby interbase 
positions as the result of the destabilization of the π-stacking interactions. This phenomenon may 
 35 
also explain the apparent higher degree of platination and consequent band fading observed by gel 
electrophoresis for this complex (Figure 2). 
Cell viability assays. The potential application of such metalloswitches as a novel type of 
photochemotherapeutic agents was examined through the evaluation of the effect of the open and 
closed isomers of C1-C7 (only the open form in the case of C6) on cancer cell proliferation and 
survivability. Five cancer cell lines were selected for these studies, namely A549 (lung 
adenocarcinoma), A375 (melanoma), MCF7 (breast carcinoma), SW620 (colorectal 
adenocarcinoma) and SKOV3 (ovarian adenocarcinoma). 
In a first instance, single-point screening assays at constant complex concentrations, i.e. 10 and 
50 μM, were performed to obtain a general comparative estimation of the cytotoxic behaviour of 
both photoisomers of each complex. The results achieved after an incubation time of 48 h are 
depicted in Figure 5 for complex C2, Figure 6 for C6 and Figure S6 for C1, C3-C5 and C7. 
Surprisingly (considering the DNA-binding studies), most of the screened platinum(II) complexes 
exhibit very poor cytotoxic properties; moreover, there is no discrimination between the activity 
of their open and closed isomers. Hence, treatment of the cells with open/closed C1, C3, C4 and 
C5 gives rise to above 75% survival of the cell populations (Figure S6). Mononuclear C7 shows 
slightly better results, especially for the SKOV3 cell line, for which the closed form is more active 
than the open one (Figure S6). At [C7] = 10 μM, closed C7 can induce 50% growth inhibition, 
whereas cell viability of around 95% is observed with the open form. Much more favorable results 
were achieved with compound C2. Indeed, whereas the open form of this complex is not active in 
all tested cell lines, its closed photoisomer presents a remarkably high cytotoxic activity against 
most of them (Figure 5). For instance, incubation of the cells with 50 μM C2 led to survival levels 
below 35% in all cases, except for the ovarian SKOV3 line. Even more interesting is the fact that 
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comparable cancer-cell death ratios were also obtained with the same cell lines using a lower 
amount of the complex, namely with a concentration of 10 μM (Figure 5). 
 
 
Figure 5. Single-point cell viability assays for the open and closed forms of C2, at constant 
complex concentrations (i.e. 10 and 50 μM) with incubation time of 48 hours. The results are given 
in % of cell viability, using five different cancer cell lines, namely A549 (lung adenocarcinoma), 
A375 (melanoma), MCF7 (breast carcinoma), SW620 (colorectal adenocarcinoma) and SKOV3 
(ovarian adenocarcinoma). The data shown are means ± SD of three independent experiments. 
 
The cell-viability results achieved with photochemically inert C6 were also noteworthy. In 
accordance with the DNA-interaction studies (see above), open C6 is highly cytotoxic, as reflected 
by the cell-death ratios of over 85% observed in all cell lines with a complex concentration of 50 
μM (Figure 6). Related high antiproliferative levels were even achieved using a complex 
concentration of 10 μM, thus highlighting the different mode of action of this imidazole-based 
compound compared with the open forms of the pyridine- and -quinoline-containing ones (which 
are not cytotoxic). 
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Subsequently, half-maximal inhibitory concentrations (IC50) were determined for the two most 
interesting platinum(II) compounds, namely C2 and C6 (Figure S7), using the two cell lines A375 
and SW620, carefully selected from the single-point results (see Figures 5 and 6) and specific 
characteristics. The melanoma A375 cells constitute the most suitable target for PACT drug 
candidates such as those herein reported, owing to the inherent accessibility to the treatment area.48 
The choice of the colorectal cancer line SW620 arises from its bad prognosis and current shortfall 
of efficient therapies.49 The IC50 for cisplatin with these two cell lines were also determined, for 
comparison purposes. 
 
 
Figure 6. Single-point cell viability assays for photoinactive C6, at constant complex 
concentrations (i.e. 10 and 50 μM) with an incubation time of 48 hours. The results are given in % 
of cell viability, using five different cancer cell lines, namely A549 (lung adenocarcinoma), A375 
(melanoma), MCF7 (breast carcinoma), SW620 (colorectal adenocarcinoma) and SKOV3 
(ovarian adenocarcinoma). The data shown are means ± SD of three independent experiments. 
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The IC50 data listed in Table 2 corroborate the single-point cell viability assays (see above) and 
the cytotoxic potential of the selected compounds, which are more efficient than cisplatin for the 
two cell lines. The IC50 values for closed C2 and open C6 are in the low micromolar range, the 
compounds being up to 8 times more active than cisplatin (Table 2). 
 
Table 2. Half-maximal inhibitory concentrations (IC50, μM) of cisplatin and complexes C2 and 
C6 for the A375 (melanoma) and SW620 (colorectal adenocarcinoma) human cell lines, after 
incubation for 48 h. The results are expressed as mean values ± SD out of three independent 
experiments. The dose-response curves are shown in Figure S8. 
Complex A375 cells SW620 cells 
Cisplatin 6.6 ± 0.6 13.5 ± 1.9 
Open C2 > 75 > 75 
Closed C2 3.1 ± 0.2 2.4 ± 0.2 
C6a 3.4 ± 0.6 1.8 ± 0.3 
a This complex does not undergo photocyclization. 
 
Circular dichroism measurements. The distinct results achieved with open C6, compared with 
those of all other open complexes, were analyzed further by circular dichroism (CD) spectroscopy. 
Thus, increasing quantities of the open form of C1-C7 were added to solutions of ct-DNA, and the 
corresponding CD spectra were recorded in the near-UV region, viz. between 235 and 315 nm, 
after incubation for 24 h at 37 °C (see Experimental Section for details). The spectra for C6 and 
open C1-C5 and C7 are shown in Figure 7. 
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Figure 7. CD spectra of ct-DNA samples ([DNA]bp = 50 μM) treated with increasing 
concentrations (5-25 μM) of open complexes C1‒C7, registered after incubation for 24 h at 37 °C. 
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Direct comparison of the CD spectra of C1 and C6 interacting with B-DNA reveals noticeable 
differences. The addition of increasing amounts of C1 to ct-DNA results in a minor bathochromic 
shift of both the characteristic positive and negative bands, and a progressive slight increase of 
ellipticity of the positive signal, up to saturation. Such CD features are indicative of the 
monofunctional covalent binding of platinum(II) drugs to DNA, and therefore agree with the 
previously proposed metal-mediated activity of the open photoisomers.50 Furthermore, these 
spectroscopic data corroborate the minor impact of the complex binding on the helical 
conformation nor on the base-pair stacking of the biomolecule. Apart from C6, similar spectra 
were obtained for all other open complexes (see Figure 7); the spectral changes induced upon 
treatment of ct-DNA with the highest concentration of each complex are listed in Table S5. 
Open C6 induces a drastically distinct alteration of the conformation of the double helix (Figure 
7 and Table S5). The progressive binding of this imidazolic species leads to a severe decrease of 
the whole CD signal of B-DNA, particularly for the negative band. These spectral changes suggest 
that C6 has a distinct effect on the secondary structure of the biomolecule, most likely generating 
local disruptions of the helical turn, and destabilization of the alignment of adjacent base pairs. 
This effect is consistent with the efficient expulsion of ethidium bromide noted by fluorescence 
assays (see above). 
Since C6 is the sole metal complex of the series exhibiting this behavior, it may be attributed to 
the methylimidazole units; however, the exact mechanism through which C6 induces such a 
distinct structural alteration of B-DNA remains to be elucidated. Probably, the specific electronic 
structure of ligand H631 has a direct effect on the ligand-exchange kinetics and/or the binding 
affinity of the platinum(II) centers, which may thus become more prone to mediate DNA cross-
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links. These different DNA-interacting properties may explain the higher cytotoxicity of C6, 
compared with that of the other open complexes (Table 2 and Figures 5, 6 and S7). 
Finally, (see Figure S6) 
 
CONCLUSIONS 
 
Following earlier promising results,1 a series of photoswitchable platinum(II) complexes based 
on photoresponsive dithienylcyclopentene moieties were prepared and fully characterized. In 
particular, the connectivity of the metal ions was clearly established by X-ray measurements, 
which revealed a trans disposition of the chlorido ligands and the S-coordination of DMSO. The 
photochemical properties of the ligands and metal complexes prepared were investigated, which 
showed that the ligand L6 and the corresponding complex C6 were photoinactive.31 
DNA-interaction studies carried out with all complexes revealed that the activity of these 
photoisomerisable agents can be efficiently modified through their light-mediated conversion. 
Clearly distinct DNA-interacting properties for the open and closed forms of the coordination 
compounds were observed. For instance, different metal covalent binding and ligand intercalative 
association were noticed for the two forms. These remarkable results suggest that the activity of 
each photoisomer may be tailored through appropriate structural modifications, thus opening up 
design possibilities for the future development of more effective DTC-based metallodrugs (DTC 
stands for Dithienylcyclopentene). 
The antiproliferative activity of the open and closed forms of the complexes were examined, 
which showed that most of the compounds surprisingly were not cytotoxic; actually, the distinct 
DNA-interacting ability of each isomer did not translate into interesting results with cells. 
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Remarkable data were though obtained with complex C2, whose closed form is highly cytotoxic 
against melanoma and colorectal cancer cells, whereas its open form is non-toxic. These drastically 
distinct behaviors of open/closed C2 further strengthen the innovative approach proposed in a 
previous proof of concept study,1 consisting in using DTC photoswitches to develop novel PACT 
agents. 
 
ASSOCIATED CONTENT 
 
Supporting Information 
The Supporting Information is available free of charge on the ACS Publications website at DOI: 
10.1021/acs.inorg-chem.xxxxxxx 
Schematic representations of the structures of L1─L7; UV-vis spectra of open/closed C1; 1H 
NMR spectra of L2 upon UV irradiation; crystal data and structure refinement for C3 and C4; 
representations of the crystal structures of C3 and C4; selected bond lengths and angles for C3 
and C4; CD data of the open complexes; CD spectra of the closed complexes; cell viability assays 
and dose response curves. 
 
Accession codes 
CCDC 1565000 and 1565001 contain the supplementary crystallographic data for this paper. 
These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by 
emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data 
Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033. 
 
 43 
AUTHOR INFORMATION 
 
Corresponding author 
*E-mail: patrick.gamez@qi.ub.es 
ORCID 
Patrick Gamez: 0000-0003-2602-9525 
Notes 
The authors declare no competing financial interest. 
 
ACKNOWLEDGEMENTS 
 
Financial support from the Spanish Ministerio de Economía y Competitividad/FEDER (projects 
CTQ2015-70371-REDT, CTQ2014-55293-P and CTQ2017-88446-R) is acknowledged. PG 
thanks the Institució Catalana de Recerca i Estudis Avançats (ICREA). This work was partially 
supported by a grant from the Spanish government and the EU (FIS PI13/00089), a grant from La 
Marató de TV3 Foundation (20132730). Also, an individual contract to LKG supported by a 
program from the Barcelona University in collaboration with Obra Social de la Fundació Bancaria 
“La Caixa” is acknowledged. This research used resources of the Advanced Light Source, which 
is a DOE Office of Science User Facility under contract no. DE-AC02-05CH11231. 
 
  
 44 
REFERENCES 
 
1. Presa, A.; Brissos, R. F.; Caballero, A. B.; Borilovic, I.; Korrodi-Gregorio, L.; Perez-
Tomas, R.; Roubeau, O.; Gamez, P., Photoswitching the Cytotoxic Properties of Platinum(II) 
Compounds. Angew. Chem. Int. Ed. 2015, 54, 4561-4565. 
2. Farrer, N. J.; Salassa, L.; Sadler, P. J., Photoactivated Chemotherapy (PACT): The 
Potential of Excited-state d-Block Metals in Medicine. Dalton Trans. 2009, 10690-10701. 
3. Phillips, D., Light Relief: Photochemistry and Medicine. Photochem. Photobiol. Sci. 2010, 
9, 1589-1596. 
4. Farrer, N. J.; Sadler, P. J., Photochemotherapy: Targeted Activation of Metal Anticancer 
Complexes. Aust. J. Chem. 2008, 61, 669-674. 
5. Benov, L., Photodynamic Therapy: Current Status and Future Directions. Med. Princ. 
Pract. 2015, 24, 14-28. 
6. Crespy, D.; Landfester, K.; Schubert, U. S.; Schiller, A., Potential Photoactivated 
Metallopharmaceuticals: From Active Molecules to Supported Drugs. Chem. Commun. 2010, 46, 
6651-6662. 
7. Smith, N. A.; Sadler, P. J., Photoactivatable Metal Complexes: From Theory to 
Applications in Biotechnology and Medicine. Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci. 2013, 
371, 13. 
 45 
8. Doherty, R. E.; Sazanovich, I. V.; McKenzie, L. K.; Stasheuski, A. S.; Coyle, R.; Baggaley, 
E.; Bottomley, S.; Weinstein, J. A.; Bryant, H. E., Photodynamic Killing of Cancer Cells by a 
Platinum(II) Complex with Cyclometallating Ligand. Sci. Rep. 2016, 6. 
9. Abadeer, N. S.; Murphy, C. J., Recent Progress in Cancer Thermal Therapy Using Gold 
Nanoparticles. J. Phys. Chem. C 2016, 120, 4691-4716. 
10. Sun, Y. J.; Joyce, L. E.; Dickson, N. M.; Turro, C., DNA Photocleavage by An Osmium(II) 
Complex in the PDT Window. Chem. Commun. 2010, 46, 6759-6761. 
11. Mari, C.; Pierroz, V.; Ferrari, S.; Gasser, G., Combination of Ru(II) Complexes and Light: 
New Frontiers in Cancer Therapy. Chem. Sci. 2015, 6, 2660-2686. 
12. van Rixel, V. H. S.; Siewert, B.; Hopkins, S. L.; Askes, S. H. C.; Busemann, A.; Siegler, 
M. A.; Bonnet, S., Green Light-induced Apoptosis in Cancer Cells by a Tetrapyridyl Ruthenium 
Prodrug Offering Two Trans Coordination Sites. Chem. Sci. 2016, 7, 4922-4929. 
13. Respondek, T.; Garner, R. N.; Herroon, M. K.; Podgorski, I.; Turro, C.; Kodanko, J. J., 
Light Activation of a Cysteine Protease Inhibitor: Caging of a Peptidomimetic Nitrile with Ru-
II(bpy)(2). J. Am. Chem. Soc. 2011, 133, 17164-17167. 
14. Albani, B. A.; Pena, B.; Leed, N. A.; de Paula, N.; Pavani, C.; Baptista, M. S.; Dunbar, K. 
R.; Turro, C., Marked Improvement in Photoinduced Cell Death by a New Tris-heteroleptic 
Complex with Dual Action: Singlet Oxygen Sensitization and Ligand Dissociation. J. Am. Chem. 
Soc. 2014, 136, 17095-17101. 
 46 
15. Brabec, V.; Pracharova, J.; Stepankova, J.; Sadler, P. J.; Kasparkova, J., Photo-Induced 
DNA Cleavage and Cytotoxicity of a Ruthenium(II) Arene Anticancer Complex. J. Inorg. 
Biochem. 2016, 160, 149-155. 
16. Loganathan, D.; Morrison, H., Effect of Ring Methylation on the Photophysical, 
Photochemical and Photobiological Properties of Cis-dichlorobis(1,10-
phenanthroline)rhodium(III)chloride. Photochem. Photobiol. 2006, 82, 237-247. 
17. Cuello-Garibo, J.-A.; James, C. C.; Siegler, M. A.; Bonnet, S., Ruthenium-Based PACT 
Compounds Based on an N,S Non-Toxic Ligand: A Delicate Balance Between Photoactivation 
and Thermal Stability. Chem. Sq. 2017, 1, 2. 
18. Brieke, C.; Rohrbach, F.; Gottschalk, A.; Mayer, G.; Heckel, A., Light-Controlled Tools. 
Angew. Chem. Int. Ed. 2012, 51, 8446-8476. 
19. Irie, M., Photochromism of Diarylethene Molecules and Crystals. Proc. Jpn. Acad. Ser. B 
Phys. Biol. Sci. 2010, 86, 472-483. 
20. Feringa, B. L.; Browne, W. R., Molecular Switches. Second ed.; Wiley-VCH: 2011. 
21. Lucas, L. N.; van Esch, J.; Kellogg, R. M.; Feringa, B. L., A New Class of Photochromic 
1,2-Diarylethenes; Synthesis and Switching Properties of Bis(3-thienyl)cyclopentenes. Chem. 
Commun. 1998, 2313-2314. 
22. Price, J. H.; Schramm, R. F.; Wayland, B. B.; Williamson, A. N., Palladium(II) and 
Platinum(II) Alkyl Sulfoxide Complexes - Examples of Sulfur-Bonded, Mixed Sulfur-Bonded and 
Oxygen-Bonded, and Totally Oxygen-Bonded Complexes. Inorg. Chem. 1972, 11, 1280-1284. 
23. SADABS and SAINT, Bruker AXS Inc.: Madison, Wisconsin, USA. 
 47 
24. Sheldrick, G. M., Crystal Structure Refinement with SHELXTL. Acta Crystallogr. Sect. A 
2015, 71, 3-8. 
25. Sheldrick, G. M., Crystal Structure Refinement with SHELXL. Acta Crystallogr. Sect. C 
2015, 71, 3-8. 
26. Sheldrick, G. M. Cell_Now and Twinabs, Madison, Wisconsin, USA. 
27. Hanazawa, M.; Sumiya, R.; Horikawa, Y.; Irie, M., Thermally Irreversible Photochromic 
Systems - Reversible Photocyclization of 1,2-Bis(2-methylbenzo[b]thiophen-3-
yl)perfluorocycloalkene Derivatives. J. Chem. Soc.-Chem. Commun. 1992, 206-207. 
28. de Jong, J. J. D.; Lucas, L. N.; Hania, R.; Pugzlys, A.; Kellogg, R. M.; Feringa, B. L.; 
Duppen, K.; van Esch, J. H., Photochromic Properties of Perhydro- and 
Perfluorodithienylcyclopentene Molecular Switches. Eur. J. Org. Chem. 2003, 1887-1893. 
29. Woodward, R. B.; Hoffmann, R., Stereochemistry of Electrocyclic Reactions. J. Am. 
Chem. Soc. 1965, 87, 395-397. 
30. Feringa, B. L., Molecular Switches. Wiley-VCH Verlag GmbH: Weinheim - New-York - 
Chichester - Brisbane - Singapore - Toronto, 2001. 
31. Presa, A.; Barrios, L.; Cirera, J.; Korrodi-Gregorio, L.; Perez-Tomas, R.; Teat, S. J.; 
Gamez, P., Non-Switching 1,2-Dithienylethene-based Diplatinum(II) Complex Showing High 
Cytotoxicity. Inorg. Chem. 2016, 55, 5356-5364. 
32. Elding, L. I.; Groning, O., Kinetics and Mechanism for Ligand Substitution-Reactions of 
Square-Planar (Dimethyl Sulfoxide)Platinum(II) Complexes - Stability and Reactivity 
Correlations. Inorg. Chem. 1978, 17, 1872-1880. 
 48 
33. Kukushkin, Y. N., Contribution of Investigations of Dimethylsulfoxide Complexes in 
Coordination Chemistry Theory. Koord. Khim. 1997, 23, 163-174. 
34. Zheng, F.; Hutton, A. T.; van Sittert, C.; Moss, J. R.; Mapolie, S. F., Synthesis, Structural 
Characterization and Cis-trans Isomerization of Novel (Salicylaldiminato)platinum(II) 
Complexes. Dalton Trans. 2013, 42, 11163-11179. 
35. Snelders, D. J. M.; Siegler, M. A.; von Chrzanowski, L. S.; Spek, A. L.; van Koten, G.; 
Gebbink, R., Coulombic Inter-ligand Repulsion Effects on the Pt(II) Coordination Chemistry of 
Oligocationic, Ammonium-functionalized Triarylphosphines. Dalton Trans. 2011, 40, 2588-2600. 
36. Anderson, C. M.; Taylor, I. R.; Tibbetts, M. F.; Philpott, J.; Hu, Y. F.; Tanski, J. M., 
Hetero-multinuclear Ruthenium(III)/Platinum(II) Complexes That Potentially Exhibit Both 
Antimetastatic and Antineoplastic Properties. Inorg. Chem. 2012, 51, 12917-12924. 
37. Saborit, J. M.; Caubet, A.; Brissos, R. F.; Korrodi-Gregorio, L.; Perez-Tomas, R.; 
Martinez, M.; Gamez, P., pH-Driven Preparation of Two Related Platinum(II) Complexes 
Exhibiting Distinct Cytotoxic Properties. Dalton Trans. 2017, 46, 11214-11222. 
38. Baik, M. H.; Friesner, R. A.; Lippard, S. J., Theoretical Study of Cisplatin Binding to 
Purine Bases: Why Does Cisplatin Prefer Guanine Over Adenine? J. Am. Chem. Soc. 2003, 125, 
14082-14092. 
39. Johnstone, T. C.; Suntharalingam, K.; Lippard, S. J., The Next Generation of Platinum 
Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem. Rev. 2016, 116, 
3436-3486. 
 49 
40. Farrell, N. P., Multi-Platinum Anti-Cancer Agents. Substitution-inert Compounds for 
Tumor Selectivity and New Targets. Chem. Soc. Rev. 2015, 44, 8773-8785. 
41. Cohen, G. L.; Bauer, W. R.; Barton, J. K.; Lippard, S. J., Binding of Cis-
dichlorodiammineplatinum(II) and Trans- dichlorodiammineplatinum(II) to DNA - Evidence for 
Unwinding and Shortening of the Double Helix. Science 1979, 203, 1014-1016. 
42. Sherman, S. E.; Lippard, S. J., Structural Aspects of Platinum Anticancer Drug-Interactions 
With DNA. Chem. Rev. 1987, 87, 1153-1181. 
43. Bates, A. D.; Maxwell, A., DNA Topology. Oxford University Press: Oxford, 2005. 
44. Meyeralmes, F. J.; Porschke, D., Mechanism of Intercalation into the DNA Duble Helix 
by Ethidium. Biochemistry 1993, 32, 4246-4253. 
45. Dehkordi, M. N.; Lincoln, P., Comprehensive Study on the Binding of Iron Schiff Base 
Complex with DNA and Determining the Binding Mode. J. Fluoresc. 2013, 23, 813-821. 
46. Permyakov, E. A., Luminescent Spectroscopy of Proteins. CRC Press: Boca Raton, Florida, 
1993. 
47. Martin-Pintado, N.; Yahyaee-Anzahaee, M.; Deleavey, G. F.; Portella, G.; Orozco, M.; 
Damha, M. J.; Gonzalez, C., Dramatic Effect of Furanose C2 ' Substitution on Structure and 
Stability: Directing the Folding of the Human Telomeric Quadruplex with a Single Fluorine Atom. 
J. Am. Chem. Soc. 2013, 135, 5344-5347. 
48. Horbert, R.; Pinchuk, B.; Davies, P.; Alessi, D.; Peifer, C., Photoactivatable Prodrugs of 
Antimelanoma Agent Vemurafenib. ACS Chem. Biol. 2015, 10, 2099-2107. 
 50 
49. Aklilu, M.; Eng, C., The Current Landscape of Locally Advanced Rectal Cancer. Nat. Rev. 
Clin. Oncol. 2011, 8, 649-659. 
50. Macquet, J. P.; Butour, J. L., Circular-Dichroism Study of DNA Platinum Complexes - 
Differentiation Between Monofunctional, Cis-bidentate and Trans-bidentate Platinum Fixation on 
a Series of DNAs. Eur. J. Biochem. 1978, 83, 375-387. 
 
 
  
 51 
TOC 
 
The cytotoxic properties of platinum(II) complexes can be tuned by photoisomerization of their 
1,2-dithienylethene-containing ligands 
 
 
 
 
 
 
